Arana, A. ., Margulis, A. V., Varas-Lorenzo, C. ., Bui, C. L., Gilsenan, A. ., McQuay, L. J., … Perez-Gutthann, S. . (2020). Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5150
A. Arana
First name
A.
Last name
Arana
Phiri, K. ., Hallas, J. ., Linder, M. ., Margulis, A. ., Suehs, B. ., Arana, A. ., … Seeger, J. . (2021). A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. Curr Med Res Opin. http://doi.org/10.1080/03007995.2021.1891035
Arana, A. ., Pottegard, A. ., Kuiper, J. G., Booth, H. ., Reutfors, J. ., Calingaert, B. ., … Perez-Gutthann, S. . (2021). Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). Clinical Epidemiology. http://doi.org/https://doi.org/10.2147/CLEP.S331287
Hoffman, V. ., Hallas, J. ., Linder, M. ., Margulis, A. V., Suehs, B. T., Arana, A. ., … Seeger, J. D. (2021). Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study. Drug Saf. http://doi.org/10.1007/s40264-021-01095-7